5 Investors to Follow Other Than Warren Buffett
There is no doubt that Warren Buffett is one of…
Sell
35
BEAM Quote, Financials, Valuation and Earnings
Last price:
$17.23
Seasonality move
:
29.84%
Day range:
$15.51 - $16.24
52-week range:
$13.53 - $35.25
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
21.41x
P/B ratio:
1.45x
Volume:
2.6M
Avg. volume:
2.7M
1-year change:
-27.98%
Market cap:
$1.6B
Revenue:
$63.5M
EPS (TTM):
-$4.61
Analysts' Opinion
-
Consensus RatingBeam Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 10 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $45.00, Beam Therapeutics has an estimated upside of 177.35% from its current price of $16.23.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $20.00 representing -23.27% downside risk from its current price of $16.23.
Fair Value
-
According to the consensus of 13 analysts, Beam Therapeutics has 177.35% upside to fair value with a price target of $45.00 per share.
BEAM vs. S&P 500
-
Over the past 5 trading days, Beam Therapeutics has underperformed the S&P 500 by -17.79% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Beam Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Beam Therapeutics has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Beam Therapeutics reported revenues of $7.5M.
Earnings Growth
-
Beam Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Beam Therapeutics reported earnings per share of -$1.24.
Enterprise value:
411.6M
EV / Invested capital:
0.37x
Price / LTM sales:
21.41x
EV / EBIT:
--
EV / Revenue:
6.47x
PEG ratio (5yr expected):
-0.02x
EV / Free cash flow:
-1.14x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-30.44%
Net Income Margin (TTM):
-609.24%
Return On Equity:
-43.86%
Return On Invested Capital:
-43.86%
Operating Margin:
-1596.87%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $76.7M | $360.9M | $63.6M | $7.4M | $7.5M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$361.2M | -$181.7M | -$430.7M | -$104.1M | -$119.3M | |
| EBITDA | -$337.3M | -$151.4M | -$399M | -$98.7M | -$113.8M | |
| Diluted EPS | -$4.45 | -$1.78 | -$4.61 | -$1.21 | -$1.24 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $514.6M | $1.2B | $1.1B | $1.1B | $1.2B | |
| Total Assets | $693.2M | $1.5B | $1.3B | $1.4B | $1.5B | |
| Current Liabilities | $102.1M | $218.8M | $219.9M | $187.2M | $141.5M | |
| Total Liabilities | $270.8M | $624.3M | $570.8M | $446.3M | $343.8M | |
| Total Equity | $422.4M | $829.1M | $761.5M | $913.5M | $1.1B | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$305.8M | -$139.1M | -$351.4M | -$99.7M | -$103.9M | |
| Cash From Investing | $101.5M | -$7.1M | $113.4M | -$53.5M | -$125.1M | |
| Cash From Financing | $154.3M | $180.9M | $478.2M | $2.9M | $473.4M | |
| Free Cash Flow | -$353.5M | -$169.3M | -$361M | -$102.2M | -$106.9M | |
BEAM
Sector
Market Cap
$1.6B
$34.5M
Price % of 52-Week High
46.03%
43.57%
Dividend Yield
0%
0%
Shareholder Yield
-23.99%
-0.79%
1-Year Price Total Return
-27.99%
-42.08%
Beta (5-Year)
2.349
0.660
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$18.94
200-day SMA
Sell
Level
$24.84
Bollinger Bands (100)
Sell
Level
19.62 - 28.8
Chaikin Money Flow
Sell
Level
-4.4M
20-day SMA
Sell
Level
$18.14
Relative Strength Index (RSI14)
Sell
Level
37.12
ADX Line
Sell
Level
19.86
Williams %R
Buy
Level
-86.7347
50-day SMA
Sell
Level
$21.16
MACD (12, 26)
Sell
Level
-0.62
25-day Aroon Oscillator
Buy
Level
72
On Balance Volume
Neutral
Level
32.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.9458)
Sell
CA Score
(Annual)
Level (-1.1323)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (0.8092)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
Stock Forecast FAQ
In the current month, BEAM has received 10 Buy ratings 3 Hold ratings, and 0 Sell ratings. The BEAM average analyst price target in the past 3 months is $45.00.
-
Where Will Beam Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Beam Therapeutics share price will rise to $45.00 per share over the next 12 months.
-
What Do Analysts Say About Beam Therapeutics?
Analysts are divided on their view about Beam Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Beam Therapeutics is a Sell and believe this share price will drop from its current level to $20.00.
-
What Is Beam Therapeutics's Price Target?
The price target for Beam Therapeutics over the next 1-year time period is forecast to be $45.00 according to 13 Wall Street analysts, 10 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is BEAM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Beam Therapeutics is a Buy. 10 of 13 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of BEAM?
You can purchase shares of Beam Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Beam Therapeutics shares.
-
What Is The Beam Therapeutics Share Price Today?
Beam Therapeutics was last trading at $17.23 per share. This represents the most recent stock quote for Beam Therapeutics. Yesterday, Beam Therapeutics closed at $16.23 per share.
-
How To Buy Beam Therapeutics Stock Online?
In order to purchase Beam Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is BYD a Threat To Tesla Shareholders?
BYD (OTC:BYDDY) has rocketed to the top of China’s booming…
CVX Vs XOM Stock, Which Energy Play Is Best?
Chevron (NYSE:CVX) and Exxon Mobil (NYSE:XOM) are two of the…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Buy
60
RGC alert for May 8
Regencell Bioscience Holdings [RGC] is up 10.54% over the past day.
Buy
92
TPB alert for May 8
Turning Point Brands [TPB] is down 6.67% over the past day.
Buy
74
LIVN alert for May 8
LivaNova PLC [LIVN] is up 1.33% over the past day.
